The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Kaya, Gizem A ^a   Coşkun, Ayse N ^a   Yilmaz, Vuslat ^a   Oflazer, Piraye ^a   Gülsen Parman, Yeşim ^a   Aysal, Fikret ^b   Disci, Rian ^a   Direskeneli, Haner ^c   Marx, Alexander ^d   Deymeer, Feza ^a   Saruhan Direskeneli, Güher ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Bakirkoy Hospital for Psychiatric and Neurological Diseases   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; NICOTINIC RECEPTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PRIMER DNA; PTPN22 PROTEIN, HUMAN;

BLOOD; GENE FREQUENCY; GENETIC ASSOCIATION; GENETICS; GENOTYPE; HUMAN; METABOLISM; MISSENSE MUTATION; MYASTHENIA GRAVIS; ONSET AGE; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TURKEY;

AGE OF ONSET; AUTOANTIBODIES; DNA PRIMERS; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LOGISTIC MODELS; MUTATION, MISSENSE; MYASTHENIA GRAVIS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RECEPTORS, NICOTINIC; TURKEY;

EID: 84905986608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104760     Document Type: Article

References (39)

1. Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48: 1246-1252. (Pubitemid 16229407)
2. Lindstrom J, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
3. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, et al. (2001) Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368. (Pubitemid 32224355)
4. Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2012) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69: 418-422.
5. Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, et al. (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259: 427-435.
6. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, et al. (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69: 445-451.
7. Zhang B, Shen C, Bealmear B, Ragheb S, Xiong W-C, et al. (2014) Autoantibodies to agrin in myasthenia gravis patients. PLoS ONE 9: e91816.
8. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579-601. (Pubitemid 10001182)
9. Aarli JA, Romi F, Skeie GO, Gilhus NE (2003) Myasthenia gravis in individuals over 40. Ann N Y Acad Sci 998: 424-431. (Pubitemid 37194194)
10. Romi F, Gilhus NE, Varhaug JE, Myking A, Skeie GO, et al. (2003) Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis. Ann N Y Acad Sci 998: 481-490. (Pubitemid 37194201)
11. Somnier FE, Skeie GO, Aarli JA, Trojaborg W (1999) EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis. Eur J Neurol 6: 555-563. (Pubitemid 30028810)
12. Ishii W, Matsuda M, Hanyuda M, Momose M, Nakayama J, et al. (2007) Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci 14: 110-115. (Pubitemid 44855614)
13. Maniaol AH, Elsais A, Lorentzen AR, Owe JF, Viken MK, et al. (2012) Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 7: e36603.
14. Chuang WY, Strobel P, Bohlender-Willke AL, Rieckmann P, Nix W, et al. (2013) Late-onset myasthenia gravis - CTLA4 genotype association and low-for-age thymic output of naive T cells. J Autoimmun: 1-8.
15. Gregersen PK, Kosoy R, Lee AT, Lamb J, Sussman J, et al. (2012) Risk for myasthenia gravis maps to a (151) Pro->Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 72: 927-935.
16. Mustelin T, Vang T, Bottini N (2005) Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 5: 43-57. (Pubitemid 40070330)
17. Strobel P, Murumagi A, Klein R, Luster M, Lahti M, et al. (2007) Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 211: 563-571. (Pubitemid 46502433)
18. Vang T, Miletic AV, Bottini N, Mustelin T (2007) Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 40: 453-461. (Pubitemid 47343357)
19. Fousteri G, Liossis SN, Battaglia M (2013) Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. Clin Immunol 149: 556-565.
20. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais J-P, et al. (2006) Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 59: 404-407. (Pubitemid 43202499)
21. Chuang WY, Strobel P, Belharazem D, Rieckmann P, Toyka KV, et al. (2009) The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes Immun 10: 667-672.
22. Greve B, Hoffmann P, Illes Z, Rozsa C, Berger K, et al. (2009) The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. Hum Immunol 70: 540-542.
23. Lefvert AK, Zhao Y, Ramanujam R, Yu S, Pirskanen R, et al. (2008) PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol 197: 110-113.
24. Provenzano C, Ricciardi R, Scuderi F, Maiuri MT, Maestri M, et al. (2012) PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data. Neuromuscul Disord 22: 131-138.
25. Huang D, Zheng C, Giscombe R, Matell G, Pirskanen R, et al. (1999) Polymorphisms at -174 and in the 3′-flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. J Neuroimmunol 101: 197-200. (Pubitemid 29516460)
26. Nelis M, Esko T, Magi R, Zimprich F, Zimprich A, et al. (2009) Genetic structure of Europeans: a view from the North-East. PLoS One 4: e5472.
27. Mori M, Yamada R, Kobayashi K, Kawaida R, Yamamoto K (2005) Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J Hum Genet 50: 264-266. (Pubitemid 40922327)
28. Pierer M, Kaltenhauser S, Arnold S, Wahle M, Baerwald C, et al. (2006) Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. Arthritis Res Ther 8: R75.
29. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475-490.
30. Saruhan-Direskeneli G, Esin S, Baykan-Kurt B, Ornek I, Vaughan R, et al. (1997) HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol 55: 59-65. (Pubitemid 27419323)
31. Bartoccioni E, Scuderi F, Augugliaro A, Chiatamone Ranieri S, Sauchelli D, et al. (2009) HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72: 195-197.
32. Marrosu MG, Muntoni F, Murru MR, Spinicci G, Pischedda MP, et al. (1988) Sardinian multiple sclerosis is associated with HLA-DR4: a serologic and molecular analysis. Neurology 38: 1749-1753. (Pubitemid 18265041)
33. Alahgholi-Hajibehzad M, Yilmaz V, Gulsen-Parman Y, Aysal F, Oflazer P, et al. (2013) Association of HLA-DRB1(*)14, -DRB1(*)16 and -DQB1(*)05 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol 74: 1633-1635.
34. Janer M, Cowland A, Picard J, Campbell D, Pontarotti P, et al. (1999) A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. Hum Immunol 60: 909-917. (Pubitemid 29476782)
35. Dempfle A, Hein R, Beckmann L, Scherag A, Nguyen TT, et al. (2007) Comparison of the power of haplotype-based versus single- and multilocus association methods for gene x environment (gene x sex) interactions and application to gene x smoking and gene x sex interactions in rheumatoid arthritis. BMC Proc 1 Suppl 1: S73.
36. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, et al. (2007) The PTPN22 C1858T functional polymorphism and autoimmune diseases-a meta-analysis. Rheumatology (Oxford) 46: 49-56. (Pubitemid 44932783)
37. Ates A, Karaaslan Y, Karatayli E, Ertugrul E, Aksaray S, et al. (2011) Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients. Tissue Antigens 78: 56-59.
38. Sahin N, Gunduz F, Inanc N, Direskeneli H, Saruhan-Direskeneli G (2009) No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey. Rheumatol Int 30: 81-83.
39. Sahin N, Aksu K, Kamali S, Bicakcigil M, Ozbalkan Z, et al. (2008) PTPN22 gene polymorphism in Takayasu's arteritis. Rheumatology 47: 634-635. (Pubitemid 351619202)